According to the analysis, people who used GLP-1 medications had a 16 percent lower risk of developing epilepsy than those ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

The list of benefits for Novo Nordisk's semaglutide keeps getting longer. Now, it seems the GLP-1 agonist could help patients with heart failure, adding to earlier studies showing it can treat ...

Elevating Aesthetic Dermatology in Rockville with Innovative Med Spa Services Under CEO Janine Shore’ Rockville, United States – December 11, 2025 / Shore Dermatology / Shore Dermatology, a ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Phoenix NP announced a continued rise in patient satisfaction across Arizona, noting that positive feedback has increased as more women seek safe, FDA-approved GLP-1 weight loss medications through ...

The ZENITH trial showed sotatercept significantly reduced death, transplant, or hospitalization risk in advanced PAH, leading ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...